Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196458 | 0.89 | MEN1 (0.50) | MEN1KMT2ACNR1ZDHHC7 | |
| SCHEMBL23696060 | 0.88 | MEN1 (0.51) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL22861772 | 0.87 | MEN1 (0.54) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL26034698 | 0.84 | MEN1 (0.51) | MEN1KMT2AMAPTCNR1 | |
| SCHEMBL25704881 | 0.83 | MEN1 (0.50) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL25922160 | 0.82 | MEN1 (0.49) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL23945215 | 0.82 | MEN1 (0.49) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL18908734 | 0.81 | KMT2A (0.63) | MEN1KMT2AMAPK1TSHRHSD17B10 | |
| SCHEMBL24497289 | 0.81 | KMT2A (0.63) | MEN1KMT2AMAPK1TSHRHSD17B10 | |
| SCHEMBL25921498 | 0.81 | MEN1 (0.47) | MEN1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118183-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118183-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885MAPK1 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.